Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer. Oncotarget (2016) 0.77

Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Front Pharmacol (2016) 0.75

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85

Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05

I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc (2010) 22.66

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04

Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16

The conformational plasticity of protein kinases. Cell (2002) 11.21

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol (2011) 8.40

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28

New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 6.03

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene (2009) 3.86

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73

The pentacovalent phosphorus intermediate of a phosphoryl transfer reaction. Science (2003) 3.41

Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties. J Mol Biol (2002) 3.36

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther (2012) 2.63

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res (2005) 2.49

Swiss-PDB Viewer (Deep View). Brief Bioinform (2001) 2.48

Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25

Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophys J (2011) 2.24

Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20

Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res (1997) 2.03

The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90

ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett (2004) 1.79

All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci (2008) 1.74

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res (2010) 1.73

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer (2012) 1.66

Molray--a web interface between O and the POV-Ray ray tracer. Acta Crystallogr D Biol Crystallogr (2001) 1.64

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev (2011) 1.57

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49

Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer (2006) 1.38

The c-erbB3/HER3 receptor in human cancer. Cancer Surv (1996) 1.12

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem (2008) 1.11

Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat (2010) 1.09

ErbBs in lung cancer. Exp Cell Res (2008) 1.07

The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev (2012) 1.04

Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic (2007) 1.00

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene (2010) 0.99

Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer (2004) 0.95

Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol Cancer Res (2009) 0.94

ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer (2006) 0.92

Pertuzumab: optimizing HER2 blockade. Clin Cancer Res (2013) 0.87

DGGE is more sensitive for the detection of somatic point mutations than direct sequencing. Biotechniques (1999) 0.85

ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell Signal (2002) 0.81

Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods. Diagn Mol Pathol (2014) 0.78

I-PV: a CIRCOS module for interactive protein sequence visualization. Bioinformatics (2015) 0.77